Incivek is owned by Vertex Pharms.
Incivek contains Telaprevir.
Incivek has a total of 2 drug patents out of which 0 drug patents have expired.
Incivek was authorised for market use on 23 May, 2011.
Incivek is available in tablet;oral dosage forms.
Incivek can be used as method of treating chronic hepatitis c.
The generics of Incivek are possible to be released after 30 May, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7820671||VERTEX PHARMS||Peptidomimetic protease inhibitors|| |
(2 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8431615||VERTEX PHARMS||Dose forms|| |
(5 years from now)
Market Authorisation Date: 23 May, 2011
Treatment: Method of treating chronic hepatitis c
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic